BR112017019190A2 - uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas - Google Patents
uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídasInfo
- Publication number
- BR112017019190A2 BR112017019190A2 BR112017019190A BR112017019190A BR112017019190A2 BR 112017019190 A2 BR112017019190 A2 BR 112017019190A2 BR 112017019190 A BR112017019190 A BR 112017019190A BR 112017019190 A BR112017019190 A BR 112017019190A BR 112017019190 A2 BR112017019190 A2 BR 112017019190A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- line
- type
- pten
- Prior art date
Links
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000013543 active substance Substances 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- -1 2,3-dihydroimidazo [1,2-c] quinazoline compound Chemical class 0.000 abstract 3
- 101100227089 Danio rerio fgfr1a gene Proteins 0.000 abstract 2
- 101100049528 Dictyostelium discoideum vps15 gene Proteins 0.000 abstract 2
- 206010014733 Endometrial cancer Diseases 0.000 abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 abstract 2
- 101150082429 FGFR4 gene Proteins 0.000 abstract 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 2
- 101150088071 fgfr2 gene Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130547P | 2015-03-09 | 2015-03-09 | |
| PCT/EP2016/054728 WO2016142313A1 (en) | 2015-03-09 | 2016-03-07 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017019190A2 true BR112017019190A2 (pt) | 2018-04-24 |
Family
ID=55484986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017019190A BR112017019190A2 (pt) | 2015-03-09 | 2016-03-07 | uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20180042929A1 (enExample) |
| EP (1) | EP3268005A1 (enExample) |
| JP (1) | JP2018512403A (enExample) |
| KR (1) | KR20180013850A (enExample) |
| CN (1) | CN107683138A (enExample) |
| AU (1) | AU2016231260A1 (enExample) |
| BR (1) | BR112017019190A2 (enExample) |
| CA (1) | CA2978807A1 (enExample) |
| CL (1) | CL2017002284A1 (enExample) |
| EA (1) | EA201791975A1 (enExample) |
| HK (1) | HK1250645A1 (enExample) |
| IL (1) | IL254168A0 (enExample) |
| MA (1) | MA43840A (enExample) |
| MX (1) | MX2017011607A (enExample) |
| PH (1) | PH12017501644A1 (enExample) |
| SG (1) | SG11201707239WA (enExample) |
| TN (1) | TN2017000385A1 (enExample) |
| WO (1) | WO2016142313A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| MX2015014171A (es) | 2013-04-08 | 2015-12-16 | Bayer Pharma AG | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas. |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EA201791974A1 (ru) | 2015-03-09 | 2018-05-31 | Байер Фарма Акциенгезельшафт | Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин |
| WO2017153220A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CA3068324A1 (en) * | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
| WO2021222895A1 (en) * | 2020-05-01 | 2021-11-04 | Mayo Foundation For Medical Education And Research | Methods and materials for treating endometrial cancer |
| WO2022140467A1 (en) * | 2020-12-21 | 2022-06-30 | Samson Pharma, Llc | Topical compositions and methods of treating skin diseases and conditions with such compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008003189A (es) * | 2005-09-07 | 2008-03-18 | Serono Lab | Inhibidores de fosfoinositido 3-cinasa para el tratamiento de endometriosis. |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| JP5886271B2 (ja) * | 2010-04-16 | 2016-03-16 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン含有組合せ品 |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EP3003377A1 (en) * | 2013-05-31 | 2016-04-13 | Novartis AG | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
-
2016
- 2016-03-07 CN CN201680022080.8A patent/CN107683138A/zh active Pending
- 2016-03-07 HK HK18110118.6A patent/HK1250645A1/zh unknown
- 2016-03-07 MX MX2017011607A patent/MX2017011607A/es unknown
- 2016-03-07 JP JP2017548211A patent/JP2018512403A/ja not_active Withdrawn
- 2016-03-07 EA EA201791975A patent/EA201791975A1/ru unknown
- 2016-03-07 AU AU2016231260A patent/AU2016231260A1/en not_active Abandoned
- 2016-03-07 SG SG11201707239WA patent/SG11201707239WA/en unknown
- 2016-03-07 US US15/557,036 patent/US20180042929A1/en not_active Abandoned
- 2016-03-07 KR KR1020177027607A patent/KR20180013850A/ko not_active Withdrawn
- 2016-03-07 WO PCT/EP2016/054728 patent/WO2016142313A1/en not_active Ceased
- 2016-03-07 TN TNP/2017/000385A patent/TN2017000385A1/en unknown
- 2016-03-07 EP EP16708402.9A patent/EP3268005A1/en not_active Withdrawn
- 2016-03-07 MA MA043840A patent/MA43840A/fr unknown
- 2016-03-07 BR BR112017019190A patent/BR112017019190A2/pt not_active Application Discontinuation
- 2016-03-07 CA CA2978807A patent/CA2978807A1/en not_active Abandoned
-
2017
- 2017-08-27 IL IL254168A patent/IL254168A0/en unknown
- 2017-09-08 CL CL2017002284A patent/CL2017002284A1/es unknown
- 2017-09-08 PH PH12017501644A patent/PH12017501644A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017002284A1 (es) | 2018-05-18 |
| CA2978807A1 (en) | 2016-09-15 |
| CN107683138A (zh) | 2018-02-09 |
| MX2017011607A (es) | 2018-04-10 |
| EP3268005A1 (en) | 2018-01-17 |
| US20180042929A1 (en) | 2018-02-15 |
| HK1250645A1 (zh) | 2019-01-11 |
| WO2016142313A1 (en) | 2016-09-15 |
| KR20180013850A (ko) | 2018-02-07 |
| EA201791975A1 (ru) | 2018-03-30 |
| IL254168A0 (en) | 2017-10-31 |
| MA43840A (fr) | 2018-11-21 |
| AU2016231260A1 (en) | 2017-09-21 |
| SG11201707239WA (en) | 2017-10-30 |
| TN2017000385A1 (en) | 2019-01-16 |
| JP2018512403A (ja) | 2018-05-17 |
| PH12017501644A1 (en) | 2018-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017019190A2 (pt) | uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas | |
| BR112017019188A2 (pt) | Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas | |
| BR112014018868A2 (pt) | composto heterocíclico aromático contendo nitrogênio | |
| BR112015023483A2 (pt) | terapia de combinação | |
| BR112013025517A2 (pt) | uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas | |
| CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| BR112015020943A2 (pt) | terapia de combinação para tratamento de neoplasia | |
| BR112014033055A8 (pt) | Inibidores seletivos de delta pi3k | |
| BR112016025910A8 (pt) | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos | |
| BR112015009871A2 (pt) | composições farmacêuticas compreendendo hidromorfona e naloxona | |
| UY35268A (es) | Modulador del receptor de andrógeno 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaespiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida y sus usos | |
| EA201792650A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| JO3003B1 (ar) | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| BR112016005589A8 (pt) | composição farmacêutica líquida, e, uso da mesma | |
| EA201190236A1 (ru) | Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью | |
| BR112015031984A2 (pt) | gel biocompatível compreendendo nanopartículas e/ou agregados de nanopartículas; e kit compreendendo um gel biocompatível | |
| BR112016014530A2 (pt) | Composição para cuidado oral e uso de um copolímero de fosfato/acrilato, um agente para controle do tártaro e um veículo oralmente aceitável | |
| BR112016005000A8 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, composto | |
| GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases | |
| BR112021017829A2 (pt) | Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |